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Small-molecule BET bromodomain inhibitors (BETis)
are actively being pursued in clinical trials for the
treatment of a variety of cancers, but the mecha-
nisms of resistance to BETis remain poorly under-
stood. Using a mass spectrometry approach that
globally measures kinase signaling at the proteomic
level, we evaluated the response of the kinome to tar-
geted BETi treatment in a panel of BRD4-dependent
ovarian carcinoma (OC) cell lines. Despite initial
inhibitory effects of BETi, OC cells acquired resis-
tance following sustained treatment with the BETi
JQ1. Through application of multiplexed inhibitor
beads (MIBs) and mass spectrometry, we demon-
strate that BETi resistance is mediated by adaptive
kinome reprogramming, where activation of com-
pensatory pro-survival kinase networks overcomes
BET protein inhibition. Furthermore, drug combina-
tions blocking these kinases may prevent or delay
the development of drug resistance and enhance
the efficacy of BETi therapy.
INTRODUCTION
Epigenetic proteins involved in chromatin remodeling, such as
the bromodomain and extra-terminal domain (BET) bromodo-
main protein BRD4, have emerged as an exciting new class of
targets for the treatment of cancer. Importantly, it has been pro-
posed that BRD4 overexpression can promote tumor growth
through the enhancement of transcription of key oncogenes
such as MYC (Chapuy et al., 2013; Love´n et al., 2013). Conse-
quently, BET bromodomain inhibitors (BETis) were developed
that interfere with acetyl lysine recognition, displacing BET bro-
modomain proteins from transcriptional complexes and disrupt-
ing gene transcription (Filippakopoulos and Knapp, 2014).
Recent studies have shown that inhibition of BRD4 blocks tran-
scription of oncogenes in a number of cancer models, resulting
in tumor regression and apoptosis (Mertz et al., 2011; Puissant
et al., 2013; Segura et al., 2013; Shimamura et al., 2013). There-Cell R
This is an open access article under the CC BY-Nfore, BETis are actively being pursued in clinical trials for a num-
ber of cancers, including numerous solid cancers.
Although BETis show great promise as cancer therapeutics,
studies have demonstrated that the anti-proliferative effects
of BETis are quite variable (Lockwood et al., 2012; Mertz
et al., 2011). In addition, emerging studies have shown that can-
cer cells can acquire resistance to BETis, signifying that single-
agent therapies targeting BRD4 may not provide durable thera-
peutic response (Fong et al., 2015; Kumar et al., 2015; Rathert
et al., 2015). Recent work from our and other laboratories shows
that tumor cells can acquire resistance to targeted kinase inhib-
itor therapies through ‘‘adaptive kinome reprogramming,’’ a
process characterized by system-wide changes in kinase
signaling networks (Chandarlapaty et al., 2011; Duncan et al.,
2012; Nazarian et al., 2010; Sun et al., 2014). Specifically, tumor
cells react to inhibitor treatment by sending signals that cause
activation of protein-kinase-driven survival pathways that ulti-
mately bypass the specific drug action, allowing the tumor to
escape targeted therapies. These findings highlight the plas-
ticity of the cancer kinase network, but whether kinase-medi-
ated resistance mechanisms are involved in the resistance to
BETis is largely unknown.
In the present study, we evaluated the consequence of BET
protein inhibition on kinase signaling and explored the role of ki-
nome reprogramming in the acquisition of resistance to BETis
using a chemical proteomics approach. A recent study showing
that BRD4 activity was essential for growth and survival of
epithelial ovarian cancer (EOC) patient-derived tumor models
(Baratta et al., 2015) prompted us to explore the consequence
of targeted BETis on kinome dynamics in ovarian cancer (OC)
cell lines. Using multiplexed inhibitor beads with quantitative
mass spectrometry (MIB/MS) technology, we uncovered a
mechanism of resistance to BETis involving the activation of re-
ceptor tyrosine kinases (RTKs) and downstream signaling by
phosphatidylinositol 3-kinase (PI3K), AKT, and ERK. Ovarian
cancer cells chronically exposed to JQ1 acquire exquisite sensi-
tivity to combination therapies targeting RTKs, PI3K, or mitogen-
activated protein kinase kinase-extracellular signal-regulated ki-
nase (MEK-ERK) pathways. These critical findings suggest that
BETi therapies may have limited success as single agents in
some OCs due to adaptive kinome reprogramming and that
combination strategies involving inhibitors targeting kinaseseports 16, 1273–1286, August 2, 2016 ª 2016 The Author(s). 1273
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Dynamic Reprogramming of the Kinome in Response to Targeted BET Protein Inhibition
(A) Flowchart of experimental design. Combining MIB/MS and RNA sequencing (RNA-seq) to define the proteogenomic response of the kinome to BETi in OC
cells. RNAi and small-molecule inhibitors are used to define kinase survival functions. The kinome tree was reproduced courtesy of Cell Signaling Technology.
(B) RAS/PI3K mutation analysis of OC cell lines used in MIB/MS kinome studies.
(C) Knockdown of BRD4 causes growth arrest in a number of OC cell lines.
(D) Growth inhibition of OC cells in response to JQ1 treatment.
(E) JQ1 induces apoptosis in OC cells. OC cells were treated with escalating doses of JQ1 or a single dose of JQ1 (500 nM) and cleaved PARP protein levels
determined by blot.
(F and G) Genome-wide transcriptome analysis of JQ1-treated of OC cells determined by RNA-seq. Volcano plots of gene expression differences for A1847 and
OVCAR5 cells treated with JQ1 (500 nM) for 48 hr.
(H) JQ1 treatment reduces MYC and/or FOSL1 protein levels. OC cells were treated with escalating doses of JQ1 or a single dose of JQ1 (500 nM) and MYC and
FOSL1 protein levels determined by blot.
(I) MIB/MS-defined kinome response profiles of eight OC cell lines following 48-hr JQ1 (500 nM) treatment. Heatmap depicts SILAC-determined log2 fold changes
in MIB binding as a ratio of JQ1/DMSO. Red is JQ1 sensitive and green is JQ1 resistant based on GI50.
Data presented in (C) and (D) are from triplicate experiments (SEM). *p% 0.05 by Student’s t test. See also Figure S1 and Tables S1 and S2.and BET bromodomain proteins may be required to maximize
clinical benefit.
RESULTS
Dynamic Reprogramming of the Kinome in Response to
Targeted BET Protein Inhibition
To explore the effect of BET protein inhibition on cancer kinome
signaling, we used MIB/MS, a chemical proteomics approach1274 Cell Reports 16, 1273–1286, August 2, 2016that couples multiplexed inhibitor beads with quantitative mass
spectrometry, to monitor global changes in protein kinase
signaling (Figure 1A) (Cooper et al., 2013; Duncan et al., 2012;
Sos et al., 2014; Stuhlmiller et al., 2015). MIBs consists of a
layered mixture of immobilized ATP-competitive pan-kinase
inhibitors (Purvalanol B, VI16832, PP58, and CTx-0249885)
that enriches protein kinases from lysates based on the affinity
of individual kinases for the different immobilized inhibitors,
their kinase abundance, and the activation state of the kinase.
Monitoring both changes in kinase binding to MIBs through
quantitative proteomics and kinase expression via RNA seq-
uencing (RNA-seq) provides a comprehensive approach to
define the fraction of the kinome that is altered in response to
therapy. Growth and survival functions of MIB-defined kinases
are then interrogated by RNAi strategies, allowing rational pre-
diction of kinase inhibitor combination therapies.
Initially, to identify OC cells that require BRD4 activity for
growth and survival, we determined the effect of small interfering
RNA (siRNA)-mediated knockdown of BRD4 or small molecule
BET inhibition using JQ1 in a panel of widely used and estab-
lished OC cell lines. Notably, the OC cell line panel harbors
many of the PI3K/RAS alterations observed in ovarian carci-
nomas (Hanrahan et al., 2012), as well as a number that overex-
press the BRD4 target proteins MYC and/or FOSL1 (Figures 1B
and S1A). Knockdown of BRD4 caused significant growth inhibi-
tion in a number of OC cell lines, demonstrating that A2780,
A2780CP, OVCAR5, OVCAR3, A1847, IGROV1, and SKOV3
exhibit dependency for BRD4 activity (Figure 1C). As previously
reported (Marcotte et al., 2016; Shi and Vakoc, 2014; Zhang
et al., 2016), we observed differential sensitivity to small-mole-
cule inhibition of BRD4 with BETi JQ1, IBET151, or PF1 across
the OC cells (Figures 1D and S1B–S1D). Based on recent studies
evaluating JQ1 across cancer cell lines, we categorized the OC
cell lines as sensitive (GI50 % 0.75 mM: A2780, A1847, PEO1,
and OVCAR3) or resistant (GI50 R 0.75 mM: SKOV3, IGROV1,
A2780CP, and OVCAR5) (Marcotte et al., 2016; Puissant et al.,
2013). BETi-mediated apoptosis also varied among the OC cells,
where JQ1 induced PARP cleavage in A2780, A1847, PEO1,
OVCAR3, and SKOV3 cells, but not in IGROV1, A2780CP, and
OVCAR5 cells (Figures 1E and S1E). Analysis of global gene
expression changes, using RNA-seq in A1847 andOVCAR5 cells
following JQ1 therapy, showed that BET protein inhibition
reduced RNA levels of previously established BRD4 targets,
including, IL7R, FOXM1, CDK4, CDK6, MYC, and FOSL1, as
well as induced HEXIM1 expression, a recent biomarker of
BET protein inhibition (Figures 1F and 1G; Table S1) (Bartholo-
meeusen et al., 2012; Lockwood et al., 2012; Ott et al., 2012;
Zhang et al., 2016). Subsequent analysis bywestern blot showed
that JQ1 treatment resulted in reduced protein levels of BRD4-
targets FOSL1 and/or MYC across the OC cell lines (Figures
1H and S1F). Collectively, the response of OC cells to BETi is var-
iable, where some cell lines exhibited potent growth inhibition
and apoptosis, while other OC cells displayed inherent resis-
tance to increasing doses of the BETi.
To investigate the role of the protein kinome in promoting
resistance to BETi, the cell line panel was treated with JQ1 for
48 hr and alterations of nearly 70%of the kinomeweremeasured
using MIB/MS (Figures 1I; Table S2). Consistent with the role of
BRD4 in regulation of a large number of genes, we observed
changes in MIB binding of kinases across all kinome subfamilies
in response to JQ1 treatment. The kinome response profile of
I-BET151-treated SKOV3 or A1847 cells showed considerable
overlap with JQ1 therapy (SKOV3, r = 0.73; A1847, r = 0.72),
demonstrating that targeting BET proteins with structurally
distinct small molecules elicit similar kinome alterations (Figures
S1G and S1H; Table S2). Comparative analysis of kinome
expression levels by RNA-seq in A1847, A2780, and OVCAR5cells, following 48 hr JQ1 treatment, showed that many of the ki-
nase changes detected by MIBs were also induced or repressed
at the RNA level (R1.5-fold or%1.5-fold change), demonstrating
the marked effect of BET protein inhibition on kinase transcrip-
tion (Figures 2A–2C; Table S1). Notably, MIB-binding analysis re-
vealed a select group of kinases altered at the protein level inde-
pendent of RNA level, suggesting that inhibition of BET proteins
can also promote changes in translation, degradation, and/or
activity of protein kinases (Figures S2A–S2C).
Analysis of the MIB-binding data revealed a subset of kinases
commonly induced or repressed by 48 hr JQ1 treatment across
the eight OC cells lines independent of JQ1 responsiveness (Fig-
ure 2D; Table S2). Kinases universally induced in response to
JQ1 treatment across the OC cells were predominately involved
in positive regulation of apoptosis and function as key nodes in
the regulated intramembrane proteolysis (RIP) signaling, Hippo
signaling, transforming growth factor b (TGF-b) signaling, and
stress response signaling pathways (Figures 2E and S2D). Ki-
nases repressed by JQ1 were largely involved in cell-cycle pro-
gression, proliferation, cell survival, and RTK signaling (Figures
2F and S2D). Importantly, we observed decreased MIB binding
of a number of kinases currently being explored as drug targets
for OC (Figure 2G). Activation of the pro-apoptotic kinase STK4
(MST1) and its subsequent downstream Hippo-signaling
pathwaywas confirmed bywestern blot in PEO1 and A2780 cells
treated with JQ1 (Figure 2H). Additionally, activation of RIPK1,
JNK2 (MAPK9), TGFBR1, and MAP3K3 components of RIP
and TGF-b signaling was shown by blot in OC cells, corrobo-
rating MIB-binding data (Figure 2I). Reduced activating phos-
phorylation of ERK1, AKT, and SRC, as well as decreased
AURKA and ERK1 protein levels, was observed by western
blot following 48 hr JQ1 treatment, supporting a role for BET pro-
teins in promoting many of the essential cancer kinase pathways
(Figure 2J).
Principle-component analysis (PCA) and R-squared (r2)
regression analysis was then used to explore the variation in
MIB-determined kinome response to JQ1 among the OC cell
line panel. PCA analysis revealed that A2780, IGROV1, OVCAR3,
and PEO1 OC cells exhibited the most distinctive kinome
response profiles relative to the other OC cells, while the kinome
MIB-binding changes were most similar among the SKOV3 and
OVCAR5 or the A1847, A2780, and A2780CP OC cells (Figures
2K and S2E). Although no clear separation between JQ1-sensi-
tive and -resistant populations was observed by PCA, linear
regression analysis showed JQ1-resistant SKOV3 and OVCAR5
cells exhibited the most similar response to JQ1 with the highest
r2 value, 0.398, while JQ1-sensitive A1847 and A2780 cells re-
corded the second highest r2 value of 0.345 (Figures S2F–S2H).
BET Protein Inhibition Rewires RTK Activity in OC Cells
Recent studies investigating BETi therapies in breast and other
cancers demonstrated that BRD4 promotes the transcription
of a number of RTKs, establishing a role for BET proteins in the
regulation of RTK signaling (Stratikopoulos et al., 2015; Stuhlmil-
ler et al., 2015). Consistent with these findings, PCA analysis of
all kinase MIB-binding ratios following JQ1 treatment across
the eight OC cell lines demonstrated RTKs (red) were among
the most prominent responders to BET protein inhibitionCell Reports 16, 1273–1286, August 2, 2016 1275
Figure 2. BET Protein Inhibition Induces Variable Kinome Responses across Ovarian Cancer Cells
(A–C) Scatterplot shows overlap of kinases (in red) induced (R1.5-fold) or repressed (%1.5-fold) by 48-hr JQ1 (500 nM) treatment analyzed byMIB/MS and RNA-
seq analysis.
(D) Boxplot of statistically significant MIB-binding changes after 48-hr JQ1 treatment commonly induced or repressed across eight OC cell lines based on step-
up-adjusted p values at a false discovery rate (FDR) of < 0.05.
(E and F) Activation of pro-apoptotic kinase signaling and inhibition of proliferative kinase signaling network in JQ1-treated OC cells. Kinase network induced or
repressed by 48-hr JQ1 (500 nM) treatment across eight OC cell lines determined by STRING, Gene Ontology, and pathway enrichment analyses.
(G) Downregulation of kinases by JQ1 treatment currently being explored as therapeutic targets in OC. Heatmap depicts SILAC-determined log2 fold changes in
MIB binding as a ratio of JQ1/DMSO.
(H) JQ1-induced Hippo/MST1 signaling. OC cells were treated with JQ1 for 48 hr and protein levels determined by blot.
(I) JQ1-induced RIP and TGF-b signaling. Cells were treated with JQ1 for 48 hr and protein levels determined by blot.
(J) JQ1 treatment blocks kinase survival signaling in OC cells. Cells were treated with JQ1 (500 nM) for 48 hr and activating phosphorylation or total protein levels
of kinases determined by blot.
(K) Principal-component analysis of MIB-defined kinome response profiles across OC cell lines treated with JQ1 (500 nM) for 48 hr.
See also Figure S2 and Tables S1 and S2.(Figure 3A). These changes were also observed by RNA-seq,
confirming a role for BRD4 in the regulation of RTK expression
in OC cells (Figures S3A–S3C). A heatmap depiction of RTK
MIB-binding ratios (isolated from Figure 1I) highlights themarked
effect and heterogeneity of the RTK-reprogramming response to
BET protein inhibition across the OC cell line panel (Figure 3B).
Importantly, PCA analysis of the RTK MIBs response in the eight
OC cells showed more similar responses in JQ1-sensitive OC
cells (A2780, A1847, PEO1, and OVCAR3) than those of JQ1-
resistant OC cells (Figure 3C). These findings demonstrate that
JQ1-sensitive and resistant cells rewire their RTK networks
uniquely to BET protein inhibition.
A dose-dependent depletion of RTKs PDGFRB, DDR1, AXL,
ERBB3, and epidermal growth factor receptor (EGFR) protein1276 Cell Reports 16, 1273–1286, August 2, 2016levels was observed bywestern blot in JQ1-sensitive A1847 cells
following JQ1 therapy. This was accompanied by inhibition of
downstream RAF-MEK-ERK and AKT signaling (Figure 3D).
Analysis of global RTK tyrosine phosphorylation in these cells re-
vealed that JQ1 treatment reduces ERBB3, AXL, PDGFRB,MET,
and DDR1 phosphorylation, corroborating our MIBs studies and
demonstrating the inhibitory properties of JQ1 on RTK activity
(Figure 3E). Knockdown of PDGFRB, AXL, or DDR1 in A1847
cells blocked cell growth, suggesting that the growth inhibitory
properties of BET protein inhibition in A1847 cells are, in part,
caused by repression of multiple pro-survival RTKs (Figure S3D).
Reduced RTK activity and downstream AKT signaling were also
observed in JQ1-sensitive A2780, PEO1, andOVCAR3 cells (Fig-
ures 3F, 3G, and S3E).
Figure 3. Rewiring of the Receptor Tyrosine Kinome following BET Bromodomain Inhibition
(A) RTK response to BET inhibition in OC cells. Principal-component analysis of all MIB-defined kinases across OC cell lines treated with JQ1 (500 nM) for 48 hr.
RTKs depicted in red.
(B) RTK response of OC cells to JQ1 (500 nM) 48 hr as determined byMIB/MS. Heatmap depicts SILAC-determined log2 fold changes in MIB binding as a ratio of
JQ1/DMSO.
(C) Differential response of RTKs to JQ1 treatment between JQ1-sensitive and resistant OC cells. Principal-component analysis of all MIB-defined RTKs across
OC cell lines treated with JQ1 (500 nM) for 48 hr.
(D and E) Dose-dependent decrease in RTK protein levels and downstream survival signaling following JQ1 (500 nM) treatment for 48 hr in A1847 cells. Tyrosine
phosphorylation was inhibited by JQ1 treatment as shown by RTK array.
(F and G) JQ1-mediated repression of RTKs and AKT signaling in A2780 and PEO1 cells following JQ1 (500 nM) treatment for 48 hr.
(H and I) Dose-dependent activation of RTKs and subsequent AKT and ERK signaling in response to JQ1 48 hr treatment in JQ1-resistant OVCAR5 and SKOV3
cells depicted by western blot.
(J and K) Induced RTKs in response to 48-hr JQ1 treatment in IGROV1 and A2780CP cells depicted by western blot.
(L and M) Knockdown of FGFRs sensitizes OVCAR5 and SKOV3 cells to BET protein inhibition. Growth inhibition of OC cells in response to escalating doses of
JQ1 with or without FGFR siRNA knockdown. Data are from triplicate experiments (SEM). *p% 0.05 by Student’s t test.
See also Figure S3.Conversely, JQ1-resistant OVCAR5 and SKOV3 cell lines
showed a dose-dependent increase in expression and activity
of numerous RTKs and their downstream survival signaling path-
ways (Figures 3H and 3I). Induced expression and/or activity of
RTKs, fibroblast growth factor receptor (FGFR)1–3, EGFR, and
IGF1Rwere detected by blot in OVCAR5 and SKOV3 in response
to JQ1 treatment that was accompanied by a dose-dependent
increase in downstream P70S6 kinase, AKT, and RAF-MEK-
ERK activity. Conversely, while treatment of IGROV1 cells with
JQ1 resulted in induction of RTKs, ERBB4, FGFR2, and
FGFR3, reduced downstream signaling by P70S6K, AKT, and
ERK was observed (Figure 3J). A2780CP cells showed a pro-
nounced induction of FGFR3 protein levels, while AKT and
ERK activity remained unaltered by JQ1 treatment (Figure 3K).Collectively, BET protein inhibition reduces levels of RTKs and
downstream AKT signaling in OC cells sensitive to JQ1, whereas
in a subset of OC cells inherently resistant to JQ1, BET inhibition
activates RTKs and their downstream survival signaling.
Rapid activation of RTKs and their downstream AKT and/or
ERK signaling has been shown to promote intrinsic resistance
to a variety of targeted kinases inhibitors (Chandarlapaty et al.,
2011; Duncan et al., 2012; Nazarian et al., 2010). Combination
therapies blocking these drug-induced RTKs enhance tumor
growth inhibition and apoptosis, providing durable therapeutic
response. Importantly, RNAi-mediated knockdown of FGFR1–
3, IGF1R, or ERK2 sensitized OVCAR5 cells to JQ1, while knock-
down of FGFR2 or AKT1 sensitized SKOV3 cells to BET protein
inhibition (Figures 3L, 3M, and S3F–S3H). These findings supportCell Reports 16, 1273–1286, August 2, 2016 1277
a role for JQ1-induced RTK activation as a mechanism of resis-
tance to BET inhibition therapies.
Ovarian Cancer Cell Lines Acquire Resistance to the
BET Inhibitor JQ1 through Adaptive Kinome
Reprogramming
BETis are currently being evaluated in clinical trials for a number
of cancers, including solid tumors (Filippakopoulos and Knapp,
2014). Acquired drug resistance occurs to the majority of ther-
apies in cancer, and emerging studies suggest that BETi thera-
pies may not be sufficient as single agents to provide long-term
therapeutic benefit (Rathert et al., 2015; Shu et al., 2016). To un-
derstand the mechanistic basis for BETi resistance, we as-
sessed kinome-wide signaling alterations in OC cell line models
that had adapted to BETi after chronic exposure to the drug.
The chronically exposed OC cell lines (JQ1-R) were more resis-
tant to BETi than treatment-naive (i.e., parental cells), where
they showed a rightward shift in JQ1 dose-response cell
viability curves (Figure 4A). Additionally, A1847 and OVCAR5
JQ1-R cells showed cross-resistance to other selective BETis,
I-BET151 and OTX-015, in dose-response curves (Figures 4SA
and 4SB). Following chronic JQ1 exposure, A2780 and PEO1
failed to induce apoptosis to the extent of parental cells
following JQ1 exposure (Figures 4B and 4C). In contrast to
parental A1847 cells, treatment of A1847-R cells with increasing
doses of JQ1 was insufficient to reduce the BRD4 target gene
FOSL1 RNA or protein levels (Figures 4D and 4E). Similarly,
although JQ1 treatment resulted in the loss of BRD4 target
MYC protein in OVCAR5 parental cells, dose escalation of
JQ1 in OVCAR5-R cells was insufficient to reduce MYC protein
levels (Figure 4F).
We next compared baseline kinome profiles of OC JQ1-R cells
relative to parental cells using MIB/MS analysis to define the role
of kinase signaling in acquisition of JQ1 resistance (Figure 4G;
Table S2). OVCAR3-R cells were not analyzed by MIB/MS due
to the slow growth rate of resistant cells. PCA analysis revealed
that MIB-binding ratios of A1847, PEO1, IGROV1, A2780CP, and
A2780 JQ1-R cells reprogrammed their kinome(s) similarly, while
SKOV3-R andOVCAR5-RMIBs profilesweremore similar to one
another but distinct from the other JQ1-R cells (Figure 4H). r2
regression studies of JQ1-R cells revealed that the response of
the kinome to chronic JQ1 exposure exhibited a high degree of
heterogeneity, with no r2 values R 0.3, with the exception of
IGROV1-R and A2780-R cells (r2 = 0.387) (Figure S4C). Compar-
ative analysis of kinase expression of A1847-R and A2780-R
cells relative to parental cells by RNA-seq showed changes in
RNA expression of many of the kinases identified by MIBs, high-
lighting the continued effect of chronic JQ1 treatment on kinase
transcription (Figures 4I and 4J; Table S1).
Chronic BET Protein Inhibition Promotes Activation of
RTKs and Their Downstream PI3K/RAS Signaling in OC
Cells
Analysis of MIB-binding data of JQ1-R cells showed chronic
exposure to JQ1 promoted alterations in an assortment of can-
cer signaling pathways relative to parental cells. Increased MIB
binding of a diverse network of pro-survival RTKs was observed
among the JQ1-R OC cells relative to parental cells (Figure 5A).1278 Cell Reports 16, 1273–1286, August 2, 2016Follow-up confirmation by blot showed increased levels and/or
corresponding activating phosphorylation of RTKs FGFR1–4,
IGF1R, and/or EGFR among the JQ1-R cells, while reduced
PDGFRB levels were observed in A1847-R and A2780-R cells
relative to parental cells (Figures 5A–5C and S5A). Notably, acti-
vating phosphorylation of platelet-derived growth factor recep-
tor A (PDGFRA) or EGFR was detected in A2780-R or A1847-R
cells, respectfully, despite reduced protein levels relative to
parental cells. Analysis of RTK ligand expression by RNA-seq
in A1847-R and A2780-R cells showed increased expression of
PDGFA (A2780-R) or TGFA (A1847-R) relative to parental cells
(Figures S5B and S5C; Table S1). These findings suggest that
JQ1-R cells may promote RTK activity through increased ligand
production, despite transcriptional repression of RTKs by BET
protein inhibition.
Increased MIB-binding of the established downstream RTK
signaling MEK-ERK2 kinase signaling cascade was detected
by MIB analysis and activity of RAF, MEK, and ERK2 confirmed
by blot among JQ1-R cells (Figures 5A–5D). Induced MIB bind-
ing of the PI3K/mTOR/AKT1 pathway was detected in JQ1-R
OC cells relative to parental cells and activating phosphorylation
of AKT (T308) confirmed by blot, with the exception of SKOV3-R
cells, which showed reduced AKT (T308) levels. Notably,
elevated TGFBR1 protein levels were detected in JQ1-R
cells relative to parental cells by western blot, and increased
JAK1 levels and corresponding STAT3 phosphorylation were
observed in A2780-R. Overall, these findings demonstrate signif-
icant congruence betweenMIBs-binding and pathway activation
as assayed by western blotting. Furthermore, they indicate that
elevated signaling downstream of RTKs is a common feature in
JQ1-R OC cells.
PCA analysis was applied to search for similarities in
response to 48-hr and chronic exposure to JQ1 among the
OC cell line panel (Figures S5D and S5E). No strong similar-
ities were observed, suggesting the initial response of the ki-
nome to JQ1 is overall distinct from adaptation of the kinome
to continuous JQ1 exposure. However, a subset of kinases
induced by 48 hr JQ1 treatment remained elevated in the
JQ1-R cells relative to parental cells, while other kinases
were uniquely altered only in short-term or chronic exposure
(Figures 5E–5H and S5F–S5J). For example, PDGFRB re-
mained inhibited in A1847-R and A2780-R cells, while PRKCA,
JAK1/3, and EPHB3 were induced in both the JQ1 48-hr treat-
ment and chronically exposed A2780-R cells. Unique changes
in MIB binding were also observed in OC cells chronically
exposed to JQ1, including increased MIB binding of PDGFRA
in A2780-R cells, which was initially dramatically reduced
following JQ1 48-hr treatment and elevated DDR1 and
TYRO3 in A1847-R cells, which were both inhibited by short-
term JQ1 treatment. Elevated MIB binding of FGFRs was
commonly observed in both parental and JQ1-R OVCAR5
and SKOV3 cells (Figures 5G and 5H).
Removal of JQ1 from chronically exposedOVCAR5-R, A1847-
R, and A2780-R cells resulted in the reversal of many of the ki-
nase changes observed by sustained JQ1 treatment (Figure 5I).
Moreover, removal of JQ1 from OVCAR5-R cells resulted in loss
of FGFR1, FGFR3, and IGF1R MIB binding, demonstrating the
requirement for continuous JQ1 to maintain the RTK resistance
Figure 4. Adaptation of the OC Kinome to Chronic JQ1 Exposure
(A) OC cell lines acquire resistance to JQ1. Parental and JQ1-resistant cells were treated with escalating doses of JQ1. JQ1-R-treated cell viabilities were
normalized to DMSO-treated JQ1-R cells. Viability was assessed by CellTiter-Glo.
(B) JQ1 treatment fails to induce apoptosis in PEO1-R and A2780-R cells as shown by PARP blot.
(C) Treatment of A2780-R cells fails to induce apoptosis to the extent of parental A2780 cells as determined by Caspase-3-Glo.
(D) A1847 parental or A1847-R cells were treated with escalating doses of JQ1 for 48 hr. JQ1-mediated FOSL1/MYC protein changes were determined by
western blot.
(E) RNA levels of FOSL1 in A1847 following 4 hr, 48 hr, or chronic exposure to JQ1 (500 nM) treatment as determined by qRT-PCR.
(F) OVCAR5 and OVCAR5-R cells were treated with escalating doses of JQ1 for 48 hr. JQ1-mediated FOSL1/MYC protein changes were determined by western
blot.
(G) MIB/MS-defined kinome resistance profiles of OC cell lines following chronic exposure to JQ1 (500 nM) treatment. Heatmap depicts SILAC-determined log2
Fold changes in MIB binding as a ratio of JQ1-R/parental.
(H) Principal-component analysis (PCA) of MIB-defined kinome resistance profiles across OC cell lines chronically treated with JQ1 (500 nM). Different views of
the 3D PCA plots are shown to illustrate the grouping of kinome responses.
(I and J) Scatterplot shows overlap of kinases (in red) induced (R1.5-fold) or repressed (%1.5-fold) following chronic exposure to JQ1 (500 nM) treatment
analyzed by MIB/MS and RNA-seq analysis.
Data presented in (A) and (C) are from triplicate experiments (SEM). See also Figure S4 and Tables S1 and S2.network (Figure S5K). Consistent with the reversal of the JQ1-
induced kinome response, we observed that removal of JQ1
from A1847-R cells re-sensitizes them to JQ1 similarly to
parental A1847 cells (Figure S5L). Collectively, these findings
suggest that many of the JQ1-mediated kinome changes
involved in the adaptive kinome reprogramming response are
directly dependent on the presence of the BETi JQ1.Chronic BET Protein Inhibition Sensitizes OC Cells to
Targeted Kinase Inhibitors
Induced protein levels and/or activation of FGFR1, 2, 3, or 4 was
observed in JQ1-R cells. Therefore, we evaluated the effect of
the pan-FGFR inhibitor AZD4547 on long-term colony formation
in OC cells chronically exposed to JQ1. Blockade of the FGFR
signaling pathway resulted in a greater reduction of colonyCell Reports 16, 1273–1286, August 2, 2016 1279
Figure 5. Chronic Exposure to JQ1 Activates an Assortment of Kinase Signaling Cascades that Are Reversible
(A) Continuous JQ1 treatment of OC cell lines promotes activation of a variety of pro-survival kinase-signaling pathways. Heatmaps depict SILAC-determined
log2 fold changes in MIB binding as a ratio of JQ1-R/parental.
(B–D) Common activation of RTK signaling and their downstream AKT and ERK signaling pathways in JQ1-R cells shown by western blot.
(E–H) MIB-binding kinases induced (R1.5-fold) or repressed (%1.5-fold) following 48-hr or chronic JQ1 therapy. Scatterplot depicts common and/or unique (in
red) SILAC-determined log2 fold changes in kinase MIB binding as a ratio of 48-hr JQ1/DMSO or JQ1-R/ parental.
(I) Reversible nature of JQ1-mediated kinome response in OC cells. MIB/MS-defined kinome profiles of OC cell lines following chronic JQ1 (500 nM) treatment
or 48 hr post JQ1 removal (wash-out, WO). Heat map depicts SILAC-determined Log2 fold changes in MIB binding as a ratio of JQ1-R/ parental or JQ1-R-WO/
JQ1-R.
See also Figure S5 and Table S1.formation in JQ1-R cells relative to parental cells, demonstrating
the acquired dependency of FGFR signaling in JQ1-resistant
OC cells (Figure 6A). Moreover, RNAi-mediated depletion of1280 Cell Reports 16, 1273–1286, August 2, 2016FGFR2 resulted in a greater growth inhibition in SKOV3-R,
OVCAR5-R, and OVCAR3-R cells relative to parental cells (Fig-
ures S6A–S6C). Treatment of SKOV3-R with AZD4547 inhibits
Figure 6. Ovarian Cancer Cells Chronically Exposed to JQ1 Acquire Dependency on RTK, PI3K, and/or ERK Signaling and Exhibit Exquisite
Sensitivity to Kinase Inhibitors Targeting These Pathways
(A) Inhibition of FGFR signaling blocks growth in JQ1-R OC cells to a greater extent than parental cells in colony formation assays. Long-term 14-day colony
formation assay of JQ1-R or parental cells treated with FGFR inhibitor AZD4547 (1 mM) or DMSO.
(B and C) A1847-R cells show enhanced sensitivity to IGF1R inhibitor (GSK1904529A) or EGFR inhibitor (lapatinib) relative to parental cells. JQ1-R treated cell
viabilities were normalized to DMSO treated JQ1-R cells. Viability assessed by CellTiter-Glo.
(D) Blockade of the RTKs EGFR or IGF1R in A1847-R cells inhibits downstream kinase survival signaling as shown by blot. Cells were treated with lapatinib (1 or
3 mM) or GSK1904529A (1 or 3 mM) for 48 hr.
(E and F) A1847-R cells show enhanced sensitivity to trametinib or GDC-0941 relative to parental cells. JQ1-R-treated cell viabilities were normalized to DMSO
treated JQ1-R cells. Cell viability was assessed by CellTiter-Glo.
(G) Acquired dependency on AKT and ERK signaling in A1847-R cells. Parental A1847 cells or JQ1-R A1847 cells were transfected with siRNAs targeting PI3Ks,
AKTs, and ERK2 and cultured for 72 hr. JQ1-R knockdown cells were normalized to JQ1-R cells transfected with non-targeting siRNA.
(H) Treatment of A1847-R cells with trametinib or GDC-0941 represses FOSL1 andMYC protein levels to a greater extent than JQ1 treatment. Parental and JQ1-
resistant cells were treated with escalating doses of JQ1, GDC-0941, or trametinib for 48 hr and protein levels determined by western blot.
(I and J) Escalating doses of GDC-0941 or trametinib for 48 hr induces apoptosis and blocks RNA polymerase II phosphorylation in A1847-R cells. Protein levels
were determined by western blot.
(K) Enhanced sensitivity to PI3K inhibition across JQ1-R cells. Parental or JQ1-resistant OC cells were treated with escalating doses of GDC-0941. Viability was
assessed by CellTiter-Glo.
(L) Escalating doses of GDC-0941 for 48 hr induces apoptosis in JQ1-R cells to a greater extent than parental cells. Caspase activity was determined by Caspase-
Glo 3/7 assay according to the manufacturer.
(M) Blockade of PI3K signaling inhibits colony formation of JQ1-R OC cells. Long-term 14-day colony formation assay of JQ1-R OC cells treated with DMSO
(500 nM, JQ1), I-BET151 (2 mM), or GDC-0941 (500 nM). The dose of 500 nM GDC-0941 was selected, as it is sufficient to reduce downstream AKT activity.
Data presented in (B), (C), (E)–(G), (K), and (L) are from triplicate experiments (SEM). *p% 0.05 by Student’s t test. See also Figure S6.
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JQ1-mediated activation of FGFR, AKT, and RAF signaling and
reducesMYCprotein levels (Figure S6D). In addition to FGFR de-
pendency, enhanced sensitivity of A1847-R, OVCAR5-R, and
OVCAR3-R to siRNA-mediated knockdown or small-molecule
inhibition of IGF1R was observed relative to parental cells (Fig-
ures 6B and S6A–S6G). A1847-R cells also exhibited enhanced
sensitivity to EGFR knockdown and small molecule inhibition
of EGFR relative to parental cells (Figures 6C and S6E). Treat-
ment of A1847-R cells with either lapatinib or GSK1904529A in-
hibited JQ1-mediated activation of AKT, STAT3 and MEK-ERK
signaling (Figure 6D). These findings demonstrate that JQ1-R
cells acquire dependency on a variety of RTKs following chronic
exposure to JQ1 sensitizing these cells to RTK inhibition. Howev-
er, designing combination therapies involving RTKs and BETi
may present a challenge as each tumor cell may require blocking
unique sets of JQ1-induced RTKs in individualized therapies.
To further explore kinase vulnerabilities in the JQ1-R cells, we
carried out a kinase inhibitor screen comparing differential inhib-
itor sensitivities between A1847 parental and resistant cells (Fig-
ure S6H) using a collection of small-molecule kinase inhibitors
of well-defined target selectivity (Anastassiadis et al., 2011).
Collectively, the A1847 JQ1-R cells were shown to be more sen-
sitive than parental cells to inhibitors targeting EGFR, MEK,
PI3K/mTOR/AKT, cyclin-dependent kinase (CDK), I kappa B ki-
nase (IKK), and SRC kinases. Treatment of A1847-R cells with
the clinically relevant PI3K/mTOR inhibitor GDC-0941 or the
MEK1/2 inhibitor trametinib demonstrated that JQ1-R cells
were more sensitive to these kinase inhibitor therapies than
parental cells (Figures 6E and 6F). Additionally, knockdown of
PIK3CG, AKT1, or ERK2 resulted in greater growth inhibition in
the A1847 JQ1-R cells relative to the parental cells, signifying
that the resistant cells acquired greater dependency on the spe-
cific isoforms AKT1 and ERK2 for survival in the presence of BET
protein inhibition (Figure 6G).
Previous studies have demonstrated that phosphorylation of
either FOSL1 on S265 or MYC on S62 by ERK1/2 promotes pro-
tein stability and prevents their degradation by the proteasome
(Basbous et al., 2007; Sears et al., 2000). Importantly, trametinib
or GDC-0941 treatment in the JQ1-R cells resulted in the inhibi-
tion of ERK-mediated phosphorylation of FOSL1 (S265) and
MYC (S62), leading to the degradation of FOSL1 and MYC pro-
tein levels to a greater extent than JQ1 treatment (Figure 6H).
Furthermore, knockdown of FOSL1 or MYC decreased cell
viability to a greater extent in A1847-R cells than in parental cells,
signifying the acquired dependency of JQ1-R cells on FOSL1/
MYC signaling (Figure S6I). A more pronounced induction of
apoptosis was observed in A1847 JQ1-R cells relative to the
parental cells following treatment with either the MEK or PI3K in-
hibitor, demonstrating the increased dependence for ERK and/
or AKT activity for survival in the presence of BET protein inhibi-
tion (Figures 6I and 6J). Notably, we observed a potent reduction
in phosphorylation of RNA polymerase II at S2 in A1847-R cells in
response to MEK or PI3K inhibition. Importantly, this phosphor-
ylation event is required for transcriptional elongation of mRNA
(Ahn et al., 2004), suggesting that ERK and AKT activity may pro-
mote transcription in the absence of BET protein function.
Acquired dependency on PI3K signaling was also observed in
the other JQ1-R OC cells, where treatment of JQ1-R cells with1282 Cell Reports 16, 1273–1286, August 2, 2016GDC-0941 showed greater growth inhibition than in parental
cells (Figure 6K). RNAi-mediated knockdown of PI3K (PIK3CA,
PIK3CB and PIK3CG) in SKOV3-R cells resulted in growth inhibi-
tion to a greater extent than parental cells, while treatment of
JQ1-R cells with GDC-0941 inhibited AKT activity reduced
MYC/FOSL1 levels and blocked RNA polymerase II (S2) phos-
phorylation (Figures S6J–S6N). Importantly, treatment of JQ1-
R cells with GDC-0941 resulted in enhanced caspase-depen-
dent apoptosis relative to parental cells (Figure 6L). Evaluation
of long-term colony formation, following treatment of JQ1-R cells
with GDC-0941, showed an enhanced growth inhibition over a
14-day period relative to parental cells (Figure 6M). MEK inhibi-
tion via trametinib treatment blocked colony formation in the
A1847-R, OVCAR5-R, PEO1-R, and A2780-R cells, while AKT in-
hibition was ineffective (Figure S6O). Notably, non-tumorigenic
human immortalized ovarian surface epithelial (HIO) cell lines
formed colonies in the presence of AZD4547, trametinib or
GDC-0941, highlighting the increased sensitivity of JQ1-R cells
to FGFR, MEK, or PI3K inhibition compared to both parental
and normal ovarian epithelial cells (Figure S6P). Taken together,
treatment of OC JQ1-R cells with GDC-0941 was sufficient to
greatly reduce colony formation and induce apoptosis univer-
sally in JQ1-R cells, demonstrating the commonly acquired de-
pendency on PI3K signaling for survival in the presence of BET
protein inhibition.
Combination Therapies Targeting RTK, PI3K, or ERK
Signaling Concurrently with BET Protein Inhibitors
Enhance Growth Inhibition in OC Cell Lines
To test whether co-targeting RTK, PI3K/AKT, or MEK/ERK
signaling pathways concurrently with JQ1 can block or delay
BETi resistance, we analyzed long-term colony formation of
parental cells in response to single-agent or combination thera-
pies (Figure 7A). The combination of JQ1 and AZD4547 pre-
vented JQ1 resistant colony formation in SKOV3 and reduced
colonies in A2780 relative to single-agent therapies, while co-
treatment of JQ1 and trametinib or an ERK inhibitor, Vx-11e,
repressed JQ1-resistant colony formation in A1847, OVCAR5,
A2780, and PEO1 cells. Consistent with the observed activation
of AKT in OVCAR5 and SKOV3 following short-term BETi expo-
sure (Figures 3H and 3I), MK2206 in combination with JQ1
blocked colony formation to a greater extent than individual
agents. Importantly, blockade of the PI3K pathway with GDC-
0941, concurrently with BET protein inhibition, prevents the
development of colonies in cells initially sensitive to JQ1
(A1847, A2780, and PEO1) and those inherently resistant to
JQ1 (SKOV3 and OVCAR5). Treatment of HIO117 non-tumori-
genic ovarian epithelial cells with JQ1 reduced colony formation
and to a greater extent when combined with AZD4547; however,
no enhancement of growth inhibition was observed when JQ1
was combined with GDC-0941 or trametinib (Figure S7A). Addi-
tionally, FGFR orMEK inhibition increased JQ1-mediated growth
arrest in a subset of OC cells in 72 hr viability assays, while the
combined treatment with JQ1 and GDC-0941 blocked cell
growth to a greater extent than either agent alone across all of
the OC cell lines (Figures 7B and S7B).
Molecular analysis of OVCAR5 and SKOV3 cells treated with
JQ1 and either GDC-0941 or trametinib demonstrates the
Figure 7. Combination Therapies Targeting RTK, PI3K, or ERK Signaling Concurrently with BET Protein Inhibitors Enhance Growth Inhibition
in OC Cells
(A) Combination therapies of AZD4547 (1 mM), GDC-0941 (500 nM), MK2206 (500 nM), trametinib (10 nM) or Vx-11e (500 nM) with JQ1 (200 nM) synergistically
block cell growth of OC cells in 14-day crystal violet colony formation assay.
(B) Co-targeting BET bromodomain proteins and FGFRs, MEK, or PI3K enhances growth inhibition of parental OC cells. Cells were treated for 72 hr with JQ1
(500 nM) and AZD4547 (1 mM), BGJ398 (1 mM), trametinib (50 nM), or GDC-0941 (1 mM). Viability was assessed by CellTiter-Glo.
(C) Co-targeting BET proteins with either GDC-0941 (500 nM) or trametinib (10 nM) reduces MYC and/or FOSL1 levels to a greater extent than single agents in
OVCAR5 cells intrinsically resistant to JQ1 as depicted by blot.
(D–H) Ovarian cancer cells generated from high grade serous ovarian carcinoma (HGS-OvCa) patient-derived xenografts (PDX) grown on J2 feeder cells were
treated with escalating doses of JQ1, GDC-0941, or the combination for 72 hr and cell viability assessed by CellTiter-Glo. Chou–Talalay analysis indicated
synergy (combination index [CI] < 0.5) between GDC-0941 and JQ1 in three out of five HGS-OvCa PDX cells, with CI values shown.
(I) Resistance to BET bromodomain inhibition mediated by kinome reprogramming in OC cells. Activation of RTK-PI3K-ERK signaling promotes resistance to
JQ1, supporting combination therapies co-targeting BET proteins and RTKs, PI3K, or MEK pathways.
Data presented in (B) and (D)–(H) are from triplicate experiments (SEM). *p% 0.05 by Student’s t test. See also Figure S7 and Table S3.effectiveness of these combination therapies at blocking JQ1-
mediated activation of ERK and/or AKT signaling in OC cells
inherently resistant to JQ1 (Figures 7C and S7C). Furthermore,the combination therapies reduced levels of pMYC (S62) and
pFOSL1 (S265), leading to degradation of BRD-target MYC
and FOSL1 protein levels to a greater extent than single-agentCell Reports 16, 1273–1286, August 2, 2016 1283
therapies, as well as blocked RNA polymerase II (S2) phosphor-
ylation. These studies demonstrate that blockade of PI3K
pathway with GDC-0941, concurrently with BET protein inhibi-
tion, provides universal enhancement of JQ1 efficacy in OC cells.
To test the generality of this response, we next examined this
combination therapy in patient-derived EOC cell lines grown
on J2 feeder cells. Importantly, the combination of JQ1 and
GDC-0941 blocks cell growth to a greater extent than single
agent treatments in patient-derived EOC cell line models, with
some cells (OC-1, OC-20, and OC-16) showing drug synergy
to the combination therapy (CI < 0.5) (Figures 7D–7H; Table
S3). These findings further demonstrate the potential of targeting
both BET proteins and PI3K signaling for the treatment of OC.
DISCUSSION
In this study, we utilized MIB/MS to explore the consequence of
both short-term and chronic BET protein inhibition on global ki-
nase signaling in BRD4-dependent OC cells. Our proteomic
analysis of the response of the kinome to the BETis revealed
an essential role for BET proteins in the regulation of RTKs and
their downstream signaling in OC (Figure 7I). Short-term BET
protein inhibition resulted in reduced kinase expression of
many growth-promoting RTKs that have established roles in
tumorigenesis, as well as many kinases essential for cancer
cell growth. Additionally, we observed activation of a cell death
inducing kinase network following JQ1 treatment consistent
with the growth arrest and apoptosis observed in OC cell lines
sensitive to JQ1 therapy. To our surprise, JQ1 treatment induced
a diverse network of RTKs and their downstream AKT and ERK
survival signaling in a subset of OC cells, representing an intrinsic
mechanism of resistance to BET protein inhibition. Activation of
these RTKs and their downstream PI3K/ERK signaling pathways
was also observed in OC cells that acquired resistance to BET
protein inhibition following chronic exposure. Importantly,
blockade of JQ1-induced RTK-PI3K-ERK signaling re-sensitized
the OC cells to BET protein inhibition, resulting in potent growth
arrest and apoptosis. Our findings suggest that combination
therapies co-targeting BET proteins and kinases will overcome
resistance to BETis and provide durable responses for the treat-
ment of OC.
Emerging studies have shown that BRD4 is enriched at a num-
ber of RTK promoters in a variety of cancer models and that BET
protein inhibition displaces BRD4, resulting in reduced expres-
sion of the kinases (Stratikopoulos et al., 2015; Stuhlmiller
et al., 2015). Furthermore, BET protein inhibition has been shown
to block the induction of RTKs in response to targeted kinase in-
hibitors, overcoming drug resistance due to adaptive kinome re-
programming in both PI3K-altered and/or HER2-driven cancers.
Consistent with these findings, we demonstrate that BET protein
inhibition in OC models harboring a variety of PI3K/RAS alter-
ations reduces transcription of many RTKs, as well as other
key kinase oncogenes such as AURKA, SRC, MAPK3, and
AKT2. Moreover, we demonstrate that chronic exposure to
BETis can maintain transcriptional repression of a number of ki-
nases with established roles in feedback-mediated resistance to
kinase inhibitors. These findings suggest that pretreatment of
cancer cells with BETis may sensitize them to a wide variety of1284 Cell Reports 16, 1273–1286, August 2, 2016clinically relevant kinase inhibitors, representing a general strat-
egy to overcome resistance mediated by kinome reprogram-
ming. Interestingly, our kinome profiling studies also revealed
that BET protein inhibition induces the expression and activation
of RTKs and their downstream PI3K signaling in a subset of OC
cells as an intrinsic resistance mechanism to BETis. Contrary to
previous reports (Stratikopoulos et al., 2015; Stuhlmiller et al.,
2015), we observed activation of a variety of RTKs following
BETi treatment, suggesting that enhancement of RTK transcrip-
tion by BET proteins may be cell-type specific. The dose-depen-
dent induction of RTKs, in response to JQ1 treatment in a subset
of OC cells, suggests that BET proteins may also participate in
the negative regulation of RTKs, particularly FGFRs, which
were induced by JQ1 in the majority of OC cells. Collectively,
our findings suggest that differential sensitivity of OC cells to
JQ1 may be, in part, due to differences in BET protein regulation
of intrinsic RTK programs.
OC cells chronically exposed to JQ1 acquire sensitivity to
PI3K inhibitors, and inhibition of this pathway results in dramatic
cell growth arrest and apoptosis. Importantly, the PI3K/AKT
pathway has well-established roles in the negative regulation
of apoptosis in cancer through direct phosphorylation of pro-
apoptotic proteins (Kurokawa and Kornbluth, 2009). Recently,
studies have shown that tumor cells harboring PIK3CA muta-
tions are intrinsically resistant to BETis and require the com-
bined blockade of PI3K and BET proteins to induce tumor
apoptosis (Marcotte et al., 2016; Stratikopoulos et al., 2015).
Consistent with these findings, our analysis of kinome reprog-
ramming following short-term or chronic JQ1 exposure in
PIK3CA (H1047R) mutant SKOV3 cells revealed that BET pro-
tein inhibition activated an intrinsic resistance program consist-
ing of upregulation of FGFRs and their downstream PI3K
signaling, protecting these cells from apoptosis. Targeting the
BETi-induced RTKs or PI3K sensitized these cells to JQ1 treat-
ment, further demonstrating the utility of combining PI3K and
BET protein inhibitors to circumvent BETi resistance in PI3K-
altered cancers. Additionally, we demonstrate that an OC cell
line harboring a G12V KRAS mutation also engages RTKs and
PI3K signaling to overcome short-term BET protein inhibition,
suggesting cells harboring KRAS mutations might exhibit
intrinsic resistance to JQ1 through feedback-mediated RTK re-
programming. Further studies investigating the consequence of
KRASmutations on kinome responses to BET protein inhibition
will be required to determine whether KRAS status is predictive
of BETi response.
Recent work investigating BRD4 as a target in EOC showed
that primary human xenografts, derived from MYCN- and
c-MYC-overexpressing strains, exhibited sensitivity to BRD4
inhibitors (Baratta et al., 2015). In the present studies, we
discovered that MYC and/or FOSL1 were initially downregu-
lated by short-term JQ1 treatment in MYC- and/or FOSL1-over-
expressing OC cells; however, MYC and FOSL1 protein levels
returned to baseline following chronic JQ1 exposure. Previous
studies have demonstrated that MYC and FOSL1 protein stabil-
ity is regulated by phosphorylation by ERK (Sears et al., 2000;
Basbous et al., 2007). Importantly, we observed degradation
of MYC and FOSL1 proteins in response to MEK or PI3K inhib-
itor treatment in JQ1-R cells, but not in response to high-dose
JQ1 therapy. Thus, the elevated ERK and AKT signaling ac-
quired following continuous JQ1 therapy promotes MYC and
FOSL1 protein stability, permitting cell growth and survival in
the presence of BETis. Intriguingly, elevated FOSL1 RNA levels
were detected in A1847 JQ1-R cells, suggesting an alternative
mechanism for regulation of FOSL1 transcription in the absence
of BET protein function. Recent studies investigating resistance
mechanisms of BETis in leukemia cancers showed that activa-
tion of WNT/b-catenin and TGF-b signaling could promote
MYC signaling following chronic BET protein inhibition and
that blockade of these pathways restored sensitivity to BETis
(Fong et al., 2015; Rathert et al., 2015). In our MIB/MS studies
of JQ1-R cells, we also identified upregulation of a number of
kinases within the WNT/b-catenin and TGF-b signaling path-
ways, including ACVR1, ACVR2, and TGFBR1, as well as
CK1g1 in A1847-R cells, which showed enhanced sensitivity
to CK1 inhibitors relative to parental cells. Based on these find-
ings, an alternative transcription network, such as WNT/b-cate-
nin, could conceivably regulate the increased FOSL1 RNA
expression detected in A1847 JQ1-R cells; however, further
transcriptional studies will be required to identify epigenetic
mechanisms of resistance to JQ1 in OC cells. Nevertheless,
our studies demonstrate that treatment of JQ1-R cells with
MEK or PI3K inhibitors promotes the degradation of MYC
and/or FOSL1 at the protein level, rapidly inducing apoptosis,
representing a highly translational therapeutic strategy to over-
come BETi resistance in OC.
Collectively, we demonstrate that BET proteins promote
expression and activity of many kinases essential for cancer
cell proliferation and survival. Using MIB/MS kinome profiling,
we show that in a subset of OC cells inherently resistant to
BETis, treatment with JQ1 results in induced expression and
activation of a diverse network of RTKs and their downstream
kinase survival pathways, overcoming JQ1 drug effects.
Furthermore, OC cell lines that acquire resistance to JQ1 utilize
these RTK networks to promote downstream PI3K/ERK
signaling to block JQ1-mediated apoptosis. Importantly, OC
cells chronically exposed to JQ1 were exquisitely sensitive to
combination therapies targeting RTKs, PI3K, or MEK-ERK
pathways. These studies suggest that single-agent BETi thera-
pies may not provide durable therapeutic response in OC and
will likely require combination therapies targeting protein kinase
signaling.
EXPERIMENTAL PROCEDURES
MIB Chromatography and Liquid Chromatography Mass
Spectrometry
Experiments using MIB/MS were performed as previously described (Duncan
et al., 2012; Stuhlmiller et al., 2015). For stable isotope labeling with amino
acids in cell culture (SILAC) quantitation, equal volumes of SILAC-labeled
heavy and light lysates were mixed and endogenous kinases isolated by
MIB columns. SILAC-labeled peptides were separated on a Thermo RSLC
Ultimate 3000 UPLC through a Thermo Easy-Spray 75 mm 3 50 cm C-18
column on a 235 min gradient (4%–25% acetonitrile with 0.1% formic acid
at 300 nl/min). Thermo Q-Exactive plus ESI mass spectrometers were used.
For details, see Supplemental Experimental Procedures.
For information regarding cell growth assays, apoptotic assays, western
blotting, qRT-PCR, siRNA, RNA-seq, and drug synergy, see Supplemental
Experimental Procedures.ACCESSION NUMBERS
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